(S)-10-Hydroxycamptothecin (Synonyms: 10-羟基喜树碱; 10-HCPT; 10-Hydroxycamptothecin)

目录号: HY-N0095 纯度: 99.38%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

(S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) 是一种从喜树中分离的 DNA 拓扑异构酶 I (DNA topoisomerase I) 抑制剂。(S)-10-Hydroxycamptothecin 可显着诱导细胞凋亡，并可用于肝癌，胃癌，结肠癌和白血病的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

(S)-10-Hydroxycamptothecin Chemical Structure

CAS No. : 19685-09-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥462	In-stock
25 mg	￥420	In-stock
50 mg	￥600	In-stock
100 mg	￥950	In-stock
500 mg	￥2413	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Other Forms of (S)-10-Hydroxycamptothecin:

(±)-10-Hydroxycamptothecin In-stock
(S)-10-Hydroxycamptothecin-d5 询价
(S)-10-Hydroxycamptothecin (Standard) 询价

(S)-10-Hydroxycamptothecin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

查看所有亚型

Topoisomerase Topo I Topo II

生物活性
纯度 & 产品资料
参考文献

生物活性

(S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment^[1]^[2]^[3]^[4].

IC₅₀ & Target^[1]^[3]

Topoisomerase I

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.004 μM Compound: 2	Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
A2780	IC₅₀	0.7 μM Compound: 2, HCPT	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 19715319]
A-375	IC₅₀	0.15 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A-375	IC₅₀	27.8 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 26280921]
A-375	IC₅₀	27.8 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 25874331]
A549	IC₅₀	0.07 μM Compound: 10-OH CPT	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23566520]
A549	IC₅₀	0.08 μM Compound: 10-HCPT	Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
A549	IC₅₀	0.082 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26725027]
A549	IC₅₀	0.11 μM Compound: 6, CPT-OH	Antitumor activity against human A549/ATCC cells by SRB method Antitumor activity against human A549/ATCC cells by SRB method	[PMID: 19541483]
A549	IC₅₀	0.3 μM Compound: HCPT	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A549	IC₅₀	0.8 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28441581]
A549	IC₅₀	0.8 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27836197]
A549	IC₅₀	1.75 μM Compound: HCPT	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
A549	IC₅₀	2.75 μM Compound: HCPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30108853]
A549	IC₅₀	33.6 nM Compound: 10-HCPT	Cytotoxicity against human A549 after 72 hrs by SRB assay Cytotoxicity against human A549 after 72 hrs by SRB assay	[PMID: 22647222]
A549	IC₅₀	9.13 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30528976]
Bcap37	IC₅₀	> 20 μM Compound: HCPT	Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 23124210]
Bcap37	IC₅₀	28.1 μM Compound: HCPT	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 26280921]
Bcap37	IC₅₀	28.1 μM Compound: HCPT	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 25874331]
Bel-7402	IC₅₀	0.2 μM Compound: 2, HCPT	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 19715319]
Bel-7402	IC₅₀	0.2 μM Compound: 10-OH CPT	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 23566520]
Bel-7402	IC₅₀	0.28 μM Compound: HCP	Cytotoxicity against human Bel-7402 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human Bel-7402 cells after 72 hrs by sulforhodamine B assay	[PMID: 17067169]
Bel-7402	IC₅₀	0.36 μM Compound: HCP	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 20184290]
Bel-7402	IC₅₀	0.4 μM Compound: HCP	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 19133759]
CNE-2	IC₅₀	0.37 μM Compound: HCPT	Cytotoxicity against human CNE2 cells after 48 hrs by MTT assay Cytotoxicity against human CNE2 cells after 48 hrs by MTT assay	[PMID: 19423199]
CNE-2	IC₅₀	1.04 μM Compound: 10-HCT	Antitumor against human CNE2 cells assessed as cell survival after 48 hrs by MTT assay Antitumor against human CNE2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 21600681]
COLO 205	IC₅₀	9.1 nM Compound: 2	Cytotoxicity against human Colo 205 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human Colo 205 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
HCT-116	IC₅₀	0.021 μM Compound: 10-HCPT	Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
HCT-116	IC₅₀	0.05 μM Compound: 10-HCPT	Antiproliferative activity against human HCT-116 cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells incubated for 24 hrs by CCK-8 assay	[PMID: 35561631]
HCT-116	IC₅₀	0.3 μM Compound: 10-OH CPT	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 23566520]
HCT-116	IC₅₀	3.2 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28441581]
HCT-116	IC₅₀	3.5 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27836197]
HCT-116	IC₅₀	31.2 nM Compound: 10-HCPT	Cytotoxicity against human HCT116 after 72 hrs by SRB assay Cytotoxicity against human HCT116 after 72 hrs by SRB assay	[PMID: 22647222]
HCT-116	IC₅₀	58.62 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26725027]
HCT-8	IC₅₀	0.181 μM Compound: 2	Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
HeLa	IC₅₀	0.06 μM Compound: 10-HCPT	Antiproliferative activity against human HeLa cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells incubated for 24 hrs by CCK-8 assay	[PMID: 35561631]
HeLa	IC₅₀	10.04 μM Compound: HCPT	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28318943]
HeLa	IC₅₀	29.16 μM Compound: HCPT	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 28745887]
HepG2	IC₅₀	0.499 μM Compound: 2	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
HepG2	IC₅₀	0.981 μM Compound: 10-Hydroxy CPT	Antitumor activity against human HepG2 cells by WST-1 assay Antitumor activity against human HepG2 cells by WST-1 assay	[PMID: 21414778]
HepG2	IC₅₀	1.47 μM Compound: HCPT	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30600208]
HepG2	IC₅₀	10.1 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 27836197]
HepG2	IC₅₀	10.21 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30528976]
HepG2	IC₅₀	10.3 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28441581]
HepG2	IC₅₀	2.27 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26725027]
HepG2	IC₅₀	3.19 μM Compound: HCPT	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
HepG2	IC₅₀	3.7 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20402524]
HepG2	IC₅₀	5.4 nM Compound: 2	Cytotoxicity against human HepG2 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human HepG2 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
HepG2	IC₅₀	5.52 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 28745887]
HepG2	IC₅₀	6.49 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human Hep G2 after 48 hrs by MTT assay Cytotoxicity against human Hep G2 after 48 hrs by MTT assay	[PMID: 16933867]
HL-60	IC₅₀	0.04 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20402524]
HL-60	IC₅₀	0.11 μM Compound: 5ak	Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells	[PMID: 8410981]
HL-60	IC₅₀	0.25 μM Compound: HCPT	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23639650]
HL-60	IC₅₀	0.41 μM Compound: HCP	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 17067169]
HT-29	IC₅₀	0.21 μM Compound: 6, CPT-OH	Antitumor activity against human HT-29 cells by SRB method Antitumor activity against human HT-29 cells by SRB method	[PMID: 19541483]
HT-29	IC₅₀	8.8 nM Compound: 2	Cytotoxicity against human HT29 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human HT29 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
HUVEC	IC₅₀	18.2 μM Compound: HCPT	Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay	[PMID: 28441581]
Jurkat	IC₅₀	0.03 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 20402524]
K562	IC₅₀	0.16 μM Compound: HCP	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 20184290]
K562	IC₅₀	4.1 μM Compound: HCP	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19133759]
KB	IC₅₀	0.128 μM Compound: 2	Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay	[PMID: 25481395]
KB	IC₅₀	0.6 μM Compound: 2, HCPT	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 19715319]
KB	IC₅₀	0.6 μM Compound: 10-OH CPT	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 23566520]
KB	IC₅₀	0.829 μM Compound: 10-Hydroxy CPT	Antitumor activity against human KB cells by WST-1 assay Antitumor activity against human KB cells by WST-1 assay	[PMID: 21414778]
L02	IC₅₀	10.23 μM Compound: HCPT	Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 30528976]
L02	IC₅₀	12.83 μM Compound: HCPT	Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay	[PMID: 30108853]
L02	IC₅₀	20.4 μM Compound: HCPT	Antiproliferative activity against human L02 cells after 48 hrs by MTT assay Antiproliferative activity against human L02 cells after 48 hrs by MTT assay	[PMID: 28441581]
LoVo	IC₅₀	0.33 μM Compound: 10-HCPT	Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
MCF7	IC₅₀	19.12 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human MCF7 after 48 hrs by MTT assay Cytotoxicity against human MCF7 after 48 hrs by MTT assay	[PMID: 16933867]
MCF7	IC₅₀	2.4 μM Compound: HCPT	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27836197]
MCF7	IC₅₀	2.8 μM Compound: HCPT	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28441581]
MCF7	IC₅₀	3.58 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30600208]
MCF7	IC₅₀	48.2 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26280921]
MCF7	IC₅₀	48.2 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25874331]
MDA-MB-231	IC₅₀	0.06 μM Compound: 10-OH CPT	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 23566520]
MG-63	IC₅₀	10.69 μM Compound: HCPT	Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay	[PMID: 30528976]
MGC-803	IC₅₀	> 20 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 23124210]
MGC-803	IC₅₀	15.19 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 28745887]
MGC-803	IC₅₀	29.1 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 26280921]
MGC-803	IC₅₀	29.1 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 25874331]
MGC-803	IC₅₀	6.55 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30108853]
MGC-803	IC₅₀	6.55 μM Compound: HCPT	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
MGC-803	IC₅₀	9.71 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30528976]
NCI-H460	IC₅₀	10.08 μM Compound: HCPT	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30528976]
NCI-H460	IC₅₀	16.59 μM Compound: HCPT	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30108853]
NCI-H460	IC₅₀	38.55 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human NCI-H460 after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 after 48 hrs by MTT assay	[PMID: 16933867]
NCI-H460	IC₅₀	4.91 μM Compound: HCPT	Antiproliferative activity against human NCI-H460 cells by MTT assay Antiproliferative activity against human NCI-H460 cells by MTT assay	[PMID: 28745887]
PC-3	IC₅₀	0.078 μM Compound: 2	Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
PC-3	IC₅₀	34.5 μM Compound: HCPT	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26280921]
PC-3	IC₅₀	34.5 μM Compound: HCPT	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 25874331]
SF-268	IC₅₀	29.88 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human SF-268 after 48 hrs by MTT assay Cytotoxicity against human SF-268 after 48 hrs by MTT assay	[PMID: 16933867]
SGC-7901	IC₅₀	0.835 μM Compound: 2	Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
SMMC-7721	IC₅₀	0.14 μM Compound: HCP	Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 19842682]
T-24	IC₅₀	11.83 μM Compound: HCPT	Cytotoxicity against human T24 cells after 48 hrs by MTT assay Cytotoxicity against human T24 cells after 48 hrs by MTT assay	[PMID: 30108853]
T-24	IC₅₀	11.83 μM Compound: HCPT	Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
T-24	IC₅₀	5.53 μM Compound: HCPT	Antiproliferative activity against human T24 cells by MTT assay Antiproliferative activity against human T24 cells by MTT assay	[PMID: 28745887]
U-937	IC₅₀	0.11 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human U937 cells after 48 hrs by MTT assay Cytotoxicity against human U937 cells after 48 hrs by MTT assay	[PMID: 20402524]

体外研究
(In Vitro)

(S)-10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase^[2].
(S)-10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells^[2].
(S)-10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC₅₀ of 1.15 μM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[2]

Cell Line:	Hep G2 cells
Concentration:	5 µg/L, 10 µg/L, 20 µg/L
Incubation Time:	6 days
Result:	Hep G2 cells were mainly arrested at G2/M phase.

体内研究
(In Vivo)

(S)-10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S)-10-Hydroxycamptothecin has a 71% increase in life span (ILS)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

364.35

Formula

C₂₀H₁₆N₂O₅

CAS 号

19685-09-7

性状

固体

颜色

Light yellow to yellow

中文名称

伊立替康EP杂质B (10-Hydroxy Camptothecin)

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 50 mg/mL (137.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7446 mL	13.7231 mL	27.4461 mL
5 mM	0.5489 mL	2.7446 mL	5.4892 mL
10 mM	0.2745 mL	1.3723 mL	2.7446 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.86 mM); 悬浊液; 超声助溶

此方案可获得 2.5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.86 mM); 悬浊液; 超声助溶

此方案可获得 2.5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.38%

选择批次：

Data Sheet (626 KB) SDS (393 KB)

COA (292 KB) HNMR (171 KB) LCMS (584 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting.

[2]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8

[3]. Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35(8):1295-9. [Content Brief]

[4]. Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21(4):364-8. [Content Brief]

[5]. Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11(9):747-56. [Content Brief]

[6]. Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24(5):433-40. [Content Brief]

(S)-10-Hydroxycamptothecin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7446 mL	13.7231 mL	27.4461 mL	68.6153 mL
	5 mM	0.5489 mL	2.7446 mL	5.4892 mL	13.7231 mL
	10 mM	0.2745 mL	1.3723 mL	2.7446 mL	6.8615 mL
	15 mM	0.1830 mL	0.9149 mL	1.8297 mL	4.5744 mL
	20 mM	0.1372 mL	0.6862 mL	1.3723 mL	3.4308 mL
	25 mM	0.1098 mL	0.5489 mL	1.0978 mL	2.7446 mL
	30 mM	0.0915 mL	0.4574 mL	0.9149 mL	2.2872 mL
	40 mM	0.0686 mL	0.3431 mL	0.6862 mL	1.7154 mL
	50 mM	0.0549 mL	0.2745 mL	0.5489 mL	1.3723 mL
	60 mM	0.0457 mL	0.2287 mL	0.4574 mL	1.1436 mL
	80 mM	0.0343 mL	0.1715 mL	0.3431 mL	0.8577 mL
	100 mM	0.0274 mL	0.1372 mL	0.2745 mL	0.6862 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

(S)-10-Hydroxycamptothecin (Synonyms: 10-羟基喜树碱; 10-HCPT; 10-Hydroxycamptothecin)

Other Forms of (S)-10-Hydroxycamptothecin:

(S)-10-Hydroxycamptothecin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

(S)-10-Hydroxycamptothecin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

(S)-10-Hydroxycamptothecin (Synonyms: 10-羟基喜树碱; 10-HCPT; 10-Hydroxycamptothecin)

Other Forms of (S)-10-Hydroxycamptothecin:

(S)-10-Hydroxycamptothecin 相关抗体

(S)-10-Hydroxycamptothecin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

(S)-10-Hydroxycamptothecin 相关抗体:

摩尔计算器

稀释计算器

(S)-10-Hydroxycamptothecin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z